[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368791-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368791-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","towards-post-genomic-oncology-embracing-cancer-complexity-via-artificial-intelligence-multi-targeted-therapeutics-drug-repurposing-and-innovative-study-designs","Towards Post-Genomic Oncology - Embracing Cancer Complexity via Artificial Intelligence, Multi-Targeted Therapeutics, Drug Repurposing, and Innovative Study Designs","","Precision oncology has produced major advances by targeting defined oncogenic drivers, yet single-target efficacy is increasingly limited by cancer’s intrinsic complexity, adaptability, and evolving resistance. Solid tumors often emerge from multifactorial oncogenic processes and adjust through diverse mechanisms, reducing long-term benefit from monotherapies. This review calls for a shift toward AI-enhanced, multi-targeted strategies using high-throughput multi-omics to rationally design combinations, enabling drug discovery, repurposing, response prediction, and trial optimization to better address cancer’s biological intricacy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/towards-post-genomic-oncology-embracing-cancer-complexity-via-artificial-intelligence-multi-targeted-therapeutics-drug-repurposing-and-innovative-study-designs/368791/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/towards-post-genomic-oncology-embracing-cancer-complexity-via-artificial-intelligence-multi-targeted-therapeutics-drug-repurposing-and-innovative-study-designs/368791.png","ImageObject",300,407,{"name":42,"@type":43},"Mimi","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are single-target therapies increasingly constrained in oncology?","Question",{"text":63,"@type":64},"Their clinical efficacy is limited by cancer’s complexity and adaptability, including tumor heterogeneity, resistance mechanisms, and pathway plasticity.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What paradigm shift does the review advocate?",{"text":68,"@type":64},"It promotes multi-targeted, AI-enhanced strategies that use high-throughput multi-omic data to support the rational design of combination therapies.",{"name":70,"@type":61,"acceptedAnswer":71},"How does artificial intelligence contribute to oncology applications mentioned in the review?",{"text":72,"@type":64},"AI is used to support drug discovery and repurposing, response prediction, and clinical trial optimization based on molecular datasets.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368791,1790628342,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336477974920,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Review  \nTowards Post-Genomic Oncology: Embracing Cancer Complexity via Artificial Intelligence, Multi-Targeted Therapeutics, Drug Repurposing, and Innovative Study Designs  \nAnnabella Di Mauro 1, Massimiliano Berretta 2, Mariachiara Santorsola 1, Gerardo Ferrara 1, Carmine Picone 1, Giovanni Savarese 3 and Alessandro Ottaiano 1, *  \nAcademic Editor: Apostolos Zaravinos  \nReceived: 12 June 2025  \nRevised: 25 July 2025  \nAccepted: 9 August 2025  \nPublished: 10 August 2025  \nCitation: Di Mauro, A.; Berretta, M.; Santorsola, M.; Ferrara, G.; Picone, C.; Savarese, G.; Ottaiano, A. Towards Post-Genomic Oncology: Embracing Cancer Complexity via Artificial Intelligence, Multi-Targeted Therapeutics, Drug Repurposing, and Innovative Study Designs. Int. J. Mol. Sci. 2025, 26, 7723. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/ijms26167723](10.3390/ijms26167723)  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Istituto Nazionale Tumori di Napoli, IRCCS “G. Pascale”, Via M. Semmola, 80131 Naples, Italy; annabella.dimauro@istitutotumori.na.it (A.D.M.); [mariachiara.santorsola@istitutotumori.na.it](mariachiara.santorsola@istitutotumori.na.it) (M.S.); [gerardo.ferrara@istitutotumori.na.it](gerardo.ferrara@istitutotumori.na.it) (G.F.); [c.picone@istitutotumori.na.it](c.picone@istitutotumori.na.it) (C.P.)  \n2 Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy; [mberretta@unime.it](mberretta@unime.it)  \n3 Department of Genetics, AMES, Centro Polidiagnostico Strumentale srl, Via Padre Carmine Fico 24,  \n80013 Casalnuovo Di Napoli, Italy; [giovanni.savarese@centroames.it](giovanni.savarese@centroames.it)  \n* Correspondence: [a.ottaiano@istitutotumori.na.it](a.ottaiano@istitutotumori.na.it)  \nAbstract  \nRecent advances in precision oncology have led to significant breakthroughs through the targeting of defined oncogenic drivers. However, the clinical efficacy of single-target therapies is increasingly constrained by the intrinsic complexity and adaptability of cancer. Solid tumors frequently arise from multifactorial oncogenic processes and adapt via diverse resistance mechanisms, ultimately limiting the durability of monotherapies. This review advocates for a paradigm shift toward multi-targeted, AI-enhanced strategies that harness high-throughput multi-omic data to inform the rational design of combination therapies. By leveraging artificial intelligence for drug discovery and repurposing, response prediction, and clinical trial optimization, the field of oncology is poised to transcend reductionist approaches and more fully address the biological intricacy of cancer.  \nKeywords: target therapy; next-generation sequencing; precision oncology; artificial intelligence; tumor heterogeneity; drug repurposing  \n1. Introduction  \nCancer is a multifaceted and dynamic disease, shaped by the complex interplay among genomic alterations, signaling redundancy, clonal evolution, and the surrounding tumor microenvironment. In recent years, the paradigm of precision oncology—focused on targeting specific oncogenic drivers—has led to significant therapeutic progress. However, growing evidence underscores the limitations of single-target strategies in the context of tumor heterogeneity, resistance mechanisms, and pathway plasticity.  \nIn response to this evolving complexity, the concept of “continuously responsive oncology” is particularly compelling. This paradigm envisions cancer treatment as a dynamic and iterative process, guided by real-time molecular data, adaptive therapeutic combinations, and predictive modeling, capable of responding to the evolving biology of each patient’s tumor. Instead of relying o","cbCaitOaM06h3zqb","https://ap.wps.com/l/cbCaitOaM06h3zqb","pdf",1094564,18,"English","# Introduction\n## Continuously responsive oncology\n## Scope and structure of the review\n## Single-target limitations\n## Combination therapies and resistance\n## Liquid biopsy and NGS for real-time tracking\n## Machine learning and resistance prediction\n## Tumor microenvironment profiling\n## Synthetic lethality and drug repurposing","[{\"question\":\"Why are single-target therapies increasingly constrained in oncology?\",\"answer\":\"Their clinical efficacy is limited by cancer’s complexity and adaptability, including tumor heterogeneity, resistance mechanisms, and pathway plasticity.\"},{\"question\":\"What paradigm shift does the review advocate?\",\"answer\":\"It promotes multi-targeted, AI-enhanced strategies that use high-throughput multi-omic data to support the rational design of combination therapies.\"},{\"question\":\"How does artificial intelligence contribute to oncology applications mentioned in the review?\",\"answer\":\"AI is used to support drug discovery and repurposing, response prediction, and clinical trial optimization based on molecular datasets.\"}]","Towards Post-Genomic Oncology - Embracing Cancer Complexity via Artificial Intelligence, Multi-Targeted Therapeutics, Drug Repurposing, and Innovative Study Designs | PDF",1790178559,45,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/78c57024a21b49315c340a134c845868.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/920362d208fd294928fe67390712be38.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7750772348f6885be49b523ed8a81e2d.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ae4d845561dd286c47a24a920c17bbbd.webp",980,1385]